Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Ursula Creutzig
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Living Beings
Procedures
Chemicals & Drugs
Concepts & Ideas
Physiology
Phenomena
Anatomy
Sign-in to see full Profile
Network (preview)
35
Reinhardt, Dirk
30
Kaspers, G J L
23
Zimmermann, Martin
17
Zwaan, Christian
17
Pieters, Rob
13
Schellong, Günther
13
Hählen, Karel
11
Veerman, Anjo
10
Riehm, Hansjörg
10
Peters, Godefridus
10
Henze, Günter
10
Boos, Joachim
9
Dworzak, Michael
9
Harbott, Jochen
9
Ritter, Jörg
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Ursula Creutzig (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Lehrnbecher Thomas; Ethier Marie-Chantal; Zaoutis Theoklis; Creutzig Ursula; Gamis Alan; Reinhardt Dirk; Aplenc Richard; Sung Lillian
International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia.
British journal of haematology 2009;147(1):125-8.
-
2009: Hollink Iris H I M; van den Heuvel-Eibrink Marry M; Zimmermann Martin; Balgobind Brian V; Arentsen-Peters Susan T C J M; Alders Marielle; Willasch Andre; Kaspers Gertjan J L; Trka Jan; Baruchel Andre; de Graaf Siebold S N; Creutzig Ursula; Pieters Rob; Reinhardt Dirk; Zwaan C Michel
Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.
Blood 2009;113(23):5951-60.
-
2008: Messerer Dorle; Engel Jutta; Hasford Joerg; Schaich Markus; Ehninger Gerhard; Sauerland Cristina; Büchner Thomas; Schumacher Andrea; Krahl Rainer; Niederwieser Dietger; Krauter Jürgen; Ganser Arnold; Creutzig Ursula; Döhner Hartmut; Schlenk Richard F;
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
Haematologica 2008;93(6):826-33.
-
2008: Klusmann Jan-Henning; Creutzig Ursula; Zimmermann Martin; Dworzak Michael; Jorch Norbert; Langebrake Claudia; Pekrun Arnulf; Macakova-Reinhardt Katarina; Reinhardt Dirk
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome.
Blood 2008;111(6):2991-8.
-
2008: Meyer Lüder H; Queudeville Manon; Eckhoff Sarah M; Creutzig Ursula; Reinhardt Dirk; Karawajew Leonid; Ludwig Wolf-Dieter; Stahnke Karsten; Debatin Klaus-Michael
Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML.
Blood 2008;111(5):2899-903.
-
2008: de Jonge Hendrik J M; Weidenaar Alida C; Ter Elst Arja; Boezen H Marike; Scherpen Frank J G; Bouma-Ter Steege Jessica C A; Kaspers Gertjan J L; Goemans Bianca F; Creutzig Ursula; Zimmermann Martin; Kamps Willem A; de Bont Eveline S J M
Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):924-30.
-
2008: Creutzig Ursula; Büchner Thomas; Sauerland Maria C; Zimmermann Martin; Reinhardt Dirk; Döhner Hartmut; Schlenk Richard F
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Cancer 2008;112(3):562-71.
-
2007: Lehrnbecher T; Kaiser J; Varwig D; Ritter J; Groll A H; Creutzig U; Klingebiel T; Schwabe D
Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: analysis of the multicenter clinical trial AML-BFM 93.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2007;26(10):735-8.
-
2007: Creutzig Ursula; Diekamp Sylke; Zimmermann Martin; Reinhardt Dirk
Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Pediatric blood & cancer 2007;48(7):651-62.
-
2007: Lehrnbecher Thomas; Zimmermann Martin; Reinhardt Dirk; Dworzak Michael; Stary Jan; Creutzig Ursula
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia.
Blood 2007;109(3):936-43.
-
2006: Kaspers G J L; Reinhardt D; Fleischhack G; Armendariz H; Stark B; Zwaan C M; Zimmermann M; Creutzig U
Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML.
Pediatric blood & cancer 2006;47(5):539-42.
-
2006: Creutzig Ursula; Zimmermann Martin; Lehrnbecher Thomas; Graf Norbert; Hermann Johann; Niemeyer Charlotte M; Reiter Alfred; Ritter Jörg; Dworzak Michael; Stary Jan; Reinhardt Dirk
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(27):4499-506.
-
2006: Langebrake Claudia; Creutzig Ursula; Dworzak Michael; Hrusak Ondrej; Mejstrikova Ester; Griesinger Frank; Zimmermann Martin; Reinhardt Dirk
Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3686-92.
-
2006: Cloos J; Goemans B F; Hess C J; van Oostveen J W; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis G J; Zwaan Ch M; Kaspers G J L
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(7):1217-20.
-
2006: Zwaan Christian Michel; den Boer Monique L; Kazemier Karin M; Hählen Karel; Loonen Anne H; Reinhardt Dirk; Creutzig Ursula; Kaspers Gertjan J L; Pieters Rob
Does modulation of P-glycoprotein have clinical relevance in pediatric acute myeloid leukemia?
Blood 2006;107(12):4975-6; author reply 4976-7.
-
2006: Hubeek Isabelle; Peters Godefridus J; Broekhuizen Richard; Zwaan Christian M; Kaaijk Patricia; van Wering Elisabeth S; Gibson Brenda E S; Creutzig Ursula; Janka-Schaub Gritta E; den Boer Monique L; Pieters Rob; Kaspers Gertjan J L
In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
Haematologica 2006;91(1):17-23.
-
2006: Stam R W; Hubeek I; den Boer M L; Buijs-Gladdines J G C A M; Creutzig U; Kaspers G J L; Pieters R
MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(1):179-82.
-
2005: Hubeek I; Stam R W; Peters G J; Broekhuizen R; Meijerink J P P; van Wering E R; Gibson B E S; Creutzig U; Zwaan C M; Cloos J; Kuik D J; Pieters R; Kaspers G J L
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
British journal of cancer 2005;93(12):1388-94.
-
2005: Creutzig U; Zimmermann M; Ritter J; Reinhardt D; Hermann J; Henze G; Jürgens H; Kabisch H; Reiter A; Riehm H; Gadner H; Schellong G
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(12):2030-42.
-
2005: Goemans Bianca F; Zwaan Christian M; Harlow Amy; Loonen Anne H; Gibson Brenda E S; Hählen Karel; Reinhardt Dirk; Creutzig Ursula; Heinrich Michael C; Kaspers Gertjan J L
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Blood 2005;106(10):3532-7.
-
2005: Hubeek I; Peters G J; Broekhuizen A J F; Sargent J; Gibson B E S; Creutzig U; Kaspers G J L
Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
British journal of haematology 2005;131(2):219-22.
-
2005: Lehrnbecher T; Bernig T; Hanisch M; Koehl U; Behl M; Reinhardt D; Creutzig U; Klingebiel T; Chanock S J; Schwabe D
Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(10):1745-50.
-
2005: Goemans B F; Zwaan C M; Martinelli S; Harrell P; de Lange D; Carta C; Reinhardt D; Hählen K; Creutzig U; Tartaglia M; Heinrich M C; Kaspers G J L
Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia.
British journal of haematology 2005;130(5):801-3.
-
2005: Goemans B F; Zwaan C M; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen A H; Hählen K; Reinhardt D; Creutzig U; Kaspers G J L; Heinrich M C
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(9):1536-42.
-
2005: Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(8):1355-60.
-
2005: Reinhardt D; Diekamp S; Langebrake C; Ritter J; Stary J; Dworzak M; Schrauder A; Zimmermann M; Fleischhack G; Ludwig W-D; Harbott J; Creutzig U
Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(8):1495-6.
-
2005: Hubeek I; Peters G J; Broekhuizen A J F; Talianidis I; Sigmond J; Gibson B E S; Creutzig U; Giaccone G; Kaspers G J L
Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours.
Journal of clinical pathology 2005;58(7):695-9.
-
2005: Langebrake C; Creutzig U; Reinhardt D
Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Klinische Pädiatrie 2005;217(3):126-34.
-
2005: Langebrake Claudia; Brinkmann Iris; Teigler-Schlegel Andrea; Creutzig Ursula; Griesinger Frank; Puhlmann Ulrike; Reinhardt Dirk
Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
Cytometry. Part B, Clinical cytometry 2005;63(1):1-9.
-
2005: Puhlmann Ulrike; Ziemann Christina; Ruedell Gudrun; Vorwerk Hagen; Schaefer Dirk; Langebrake Claudia; Schuermann Peter; Creutzig Ursula; Reinhardt Dirk
Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.
The Journal of pharmacology and experimental therapeutics 2005;312(1):346-54.
-
2004: Hubeek Isabelle; Litvinova Elena; Peters Godefridus J; Broekhuizen Richard; Haarman Eric G; Huismans Dieuwke R; Cloos Jacqueline; Zwaan Christian M; Fleischhack Gudrun; Creutzig Ursula; Kaspers Gertjan J L
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
International journal of oncology 2004;25(6):1823-9.
-
2004: Creutzig Ursula; Zimmermann Martin; Reinhardt Dirk; Dworzak Michael; Stary Jan; Lehrnbecher Thomas
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(21):4384-93.
-
2004: Hubeek I; Peters G J; Broekhuizen A J F; Talianidis I; Schouten van Meeteren A Y N; van Wering E R; Gibson B; Creutzig U; Kaspers G J L
Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity.
Nucleosides, nucleotides & nucleic acids 2004;23(8-9):1351-6.
-
2004: Reinhardt D; Diekamp S; Fleischhack G; Corbacioglu C; Jürgens H; Dworzak M; Kaspers G; Creutzig U; Zwaan C M
Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia.
Onkologie 2004;27(3):269-72.
-
2004: Lehrnbecher T; Varwig D; Kaiser J; Reinhardt D; Klingebiel T; Creutzig U
Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(1):72-7.
-
2003: Hempel Georg; Reinhardt Dirk; Creutzig Ursula; Boos Joachim
Population pharmacokinetics of liposomal daunorubicin in children.
British journal of clinical pharmacology 2003;56(4):370-7.
-
2003: Zwaan Christian M; Meshinchi Soheil; Radich Jerald P; Veerman Anjo J P; Huismans Dieuwke R; Munske Leonhard; Podleschny Martina; Hählen Karel; Pieters Rob; Zimmermann Martin; Reinhardt Dirk; Harbott Jochen; Creutzig Ursula; Kaspers Gertjan J L; Griesinger Frank
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Blood 2003;102(7):2387-94.
-
2003: Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
[Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93]
Klinische Pädiatrie 2003;215(3):151-8.
-
2003: Lanvers Claudia; Reinhardt Dirk; Dübbers Angelika; Wagner-Bohn Alexandra; Creutzig Ursula; Ritter Joerg; Boos Joachim
Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia.
Medical and pediatric oncology 2003;40(5):293-301.
-
2003: Zwaan Christian M; Reinhardt Dirk; Corbacioglu Selim; van Wering Elisabeth R; Bökkerink Jos P M; Tissing Wim J E; Samuelsson Ulf; Feingold Jay; Creutzig Ursula; Kaspers Gertjan J L
Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis.
Blood 2003;101(10):3868-71.
-
2003: Kaaijk P; Kaspers G J L; Van Wering E R; Broekema G J; Loonen A H; Hählen K; Schmiegelow K; Janka-Schaub G E; Henze G; Creutzig U; Veerman A J P
Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia.
British journal of cancer 2003;88(5):775-81.
-
2002: Zwaan Christian M; Kaspers Gertjan J L; Pieters Rob; Hählen Karel; Huismans Dieuwke R; Zimmermann Martin; Harbott Jochen; Slater Rosalyn M; Creutzig Ursala; Veerman Anjo J P
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Blood 2002;100(9):3352-60.
-
2002: Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]
Klinische Pädiatrie 2002;214(4):188-94.
-
2002: Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F
[Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study]
Klinische Pädiatrie 2002;214(4):179-87.
-
2002: Reinhardt D; Thiele C; Creutzig U;
[Neuropsychological sequelae in children with AML treated with or without prophylactic CNS-irradiation]
Klinische Pädiatrie 2002;214(1):22-9.
-
2002: Zwaan Christian M; Kaspers Gertjan J L; Pieters Rob; Hählen Karel; Janka-Schaub Gritta E; van Zantwijk Christina H; Huismans Dieuwke R; de Vries Esther; Rots Marianne G; Peters Godefridus J; Jansen Gerrit; Creutzig Ursula; Veerman Anjo J P
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Blood 2002;99(1):245-51.
-
2001: Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer C M; Reinhardt D; Reiter A; Ritter J; Spaar H J; Zimmermann M;
[Improved treatment results in children with AML: Results of study AML-BFM 93]
Klinische Pädiatrie 2001;213(4):175-85.
-
2001: Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2705-13.
-
2001: Rots M G; Pieters R; Jansen G; Kaspers G J; Van Zantwijk C H; Noordhuis P; Voorn D A; Van Wering E R; Creutzig U; Veerman A J; Peters G J
A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia.
European journal of cancer (Oxford, England : 1990) 2001;37(4):492-8.
-
2000: Zwaan C M; Kaspers G J; Pieters R; Ramakers-Van Woerden N L; den Boer M L; Wünsche R; Rottier M M; Hählen K; van Wering E R; Janka-Schaub G E; Creutzig U; Veerman A J
Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Blood 2000;96(8):2879-86.
-
2000: Creutzig U; Körholz D; Niemeyer C M; Kabisch H; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children.
Klinische Pädiatrie 2000;212(4):163-8.
-
2000: Dübbers A; Würthwein G; Müller H J; Schulze-Westhoff P; Winkelhorst M; Kurzknabe E; Lanvers C; Pieters R; Kaspers G J; Creutzig U; Ritter J; Boos J
Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity.
British journal of haematology 2000;109(2):427-9.
-
2000: Creutzig U; Körholz D; Niemeyer C M; Kabisch K; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(2):340-2.
-
1999: Rots M G; Pieters R; Peters G J; van Zantwijk C H; Mauritz R; Noordhuis P; Willey J C; Hählen K; Creutzig U; Janka-Schaub G; Kaspers G J; Veerman A J; Jansen G
Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates.
Blood 1999;94(9):3121-8.
-
1999: Graubner U B; Boos J; Creutzig U; Dörffel W; Lakomek M; Niemeyer C; Schrappe M; Spaar H J; Belohradsky B H
[Antiinfectious prophylaxis in pediatric oncology. Work group "Quality Assurance" of Society for Pediatric Oncology and Hematology (GPOH)]
Klinische Pädiatrie 1999;211(4):347-52.
-
1999: Kaspers G J; Zwaan C M; Veerman A J; Rots M G; Pieters R; Bucsky P; Domula M; Göbel U; Graf N; Havers W; Jorch N; Kabisch K; Spaar H J; Ritter J; Creutzig U
Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study.
Klinische Pädiatrie 1999;211(4):239-44.
-
1999: Creutzig U; Zimmermann M; Ritter J; Henze G; Graf N; Löffler H; Schellong G
Definition of a standard-risk group in children with AML.
British journal of haematology 1999;104(3):630-9.
-
1999: Hasle H; Aricò M; Basso G; Biondi A; Cantù Rajnoldi A; Creutzig U; Fenu S; Fonatsch C; Haas O A; Harbott J; Kardos G; Kerndrup G; Mann G; Niemeyer C M; Ptoszkova H; Ritter J; Slater R; Starý J; Stollmann-Gibbels B; Testi A M; van Wering E R; Zimmermann M
Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(3):376-85.
-
1999: Rots M G; Pieters R; Peters G J; Noordhuis P; van Zantwijk C H; Kaspers G J; Hählen K; Creutzig U; Veerman A J; Jansen G
Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.
Blood 1999;93(5):1677-83.
-
1999: Den Boer M L; Pieters R; Kazemier K M; Janka-Schaub G E; Henze G; Creutzig U; Kaspers G J; Kearns P R; Hall A G; Pearson A D; Veerman A J
Different expression of glutathione S-transferase alpha, mu and pi in childhood acute lymphoblastic and myeloid leukaemia.
British journal of haematology 1999;104(2):321-7.
-
1998: Stahnke K; Boos J; Bender-Götze C; Ritter J; Zimmermann M; Creutzig U
Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(10):1534-8.
-
1998: Creutzig U; Ritter J; Boos J; Zimmermann M; Bender-Götze C; Stahnke K
[Prognosis of children with acute myelocytic leukemia after first relapse]
Klinische Pädiatrie 1998;210(4):207-11.
-
1998: Creutzig U; Bender-Götze C; Ritter J; Zimmermann M; Stollmann-Gibbels B; Körholz D; Niemeyer C
The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(5):652-9.
-
1998: den Boer M L; Pieters R; Kazemier K M; Rottier M M; Zwaan C M; Kaspers G J; Janka-Schaub G; Henze G; Creutzig U; Scheper R J; Veerman A J
Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
Blood 1998;91(6):2092-8.
-
1997: Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2247-53.
-
1997: Niemeyer C M; Arico M; Basso G; Biondi A; Cantu Rajnoldi A; Creutzig U; Haas O; Harbott J; Hasle H; Kerndrup G; Locatelli F; Mann G; Stollmann-Gibbels B; van't Veer-Korthof E T; van Wering E; Zimmermann M
Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)
Blood 1997;89(10):3534-43.
-
1996: Creutzig U; Ritter J; Vormoor J; Ludwig W D; Niemeyer C; Reinisch I; Stollmann-Gibbels B; Zimmermann M; Harbott J
Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(11):1677-86.
-
1996: Creutzig U; Ritter J; Zimmermann M; Klingebiel T
[Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients]
Klinische Pädiatrie 1996;208(4):236-41.
-
1996: Vormoor J; Boos J; Stahnke K; Jürgens H; Ritter J; Creutzig U
Therapy of childhood acute myelogenous leukemias.
Annals of hematology 1996;73(1):11-24.
-
1995: Klumper E; Pieters R; Kaspers G J; Huismans D R; Loonen A H; Rottier M M; van Wering E R; van der Does-van den Berg A; Hählen K; Creutzig U
In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(11):1864-9.
-
1995: Creutzig U; Ritter J; Ludwig W D; Niemeyer C; Reinisch I; Stollmann-Gibbels B; Zimmermann M; Harbott J
[Acute myeloid leukemia in children with Down syndrome]
Klinische Pädiatrie 1995;207(4):136-44.
-
1994: Sauter S; Kaatsch P; Creutzig U; Michaelis J
[Establishment of a uniform common data set for pediatric oncology. Applied Informatics Study Group of the GPOH (Society of Pediatric Oncology and Hematology)]
Klinische Pädiatrie 1994;206(4):306-12.
-
1993: Creutzig U; Ritter J; Ludwig W D; Harbott J; Löffler H; Schellong G
[Classification of AML by morphologic, immunologic and cytogenetic criteria. Review with reference to subtypes in the AML-BFM-87 study]
Klinische Pädiatrie 1993;205(4):272-80.
-
1993: Creutzig U; Ritter J; Zimmermann M; Schellong G
Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(2):279-86.
-
1992: Vormoor J; Ritter J; Creutzig U; Boos J; Heyen P; Ludwig W D; Harbott J; Löffler H; Schellong G
Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.
The British journal of cancer. Supplement 1992;18():S63-7.
-
1992: Stahnke K; Ritter J; Schellong G; Beck J D; Kabisch H; Lampert F; Creutzig U
[Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study]
Klinische Pädiatrie 1992;204(4):253-7.
-
1992: Creutzig U; Bender-Götze C; Klingebiel T; Ebell W; Friedrich W; Stollmann-Gibbels B; Schmidt H; Suttorp M; Gratwohl A; Heyen P
[Comparison of chemotherapy alone with allogeneic bone marrow transplantation in first full remission in children with acute myeloid leukemia in the AML-BFM-83 and AML-BFM-87 studies--matched pair analysis]
Klinische Pädiatrie 1992;204(4):246-52.
-
1992: Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G
[Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group]
Klinische Pädiatrie 1992;204(4):236-45.
-
1992: Niemeyer C; Stollmann-Gibbels B; Ebell W; Gaedicke G; Creutzig U
[Myelodysplastic diseases in childhood]
Klinische Pädiatrie 1992;204(4):190-7.
-
1990: Creutzig U; Ritter J; Vormoor J; Eschenbach C; Dickerhoff R; Burdach S; Scheel-Walter H G; Kühl J; Schellong G
[Transient myeloproliferation and acute myeloid leukemia in infants with Down's syndrome]
Klinische Pädiatrie 1990;202(4):253-7.
-
1990: Creutzig U; Niederbiermann G; Ritter J; Harbott J; Löffler H; Schellong G
Prognostic significance of eosinophilia in acute myelomonocytic leukemia in relation to induction treatment.
Haematology and blood transfusion 1990;33():226-32.
-
1990: Ritter J; Creutzig U; Reiter A; Riehm H; Schellong G
Childhood leukemia: cooperative Berlin-Frankfurt-Münster trials in the Federal Republic of Germany.
Journal of cancer research and clinical oncology 1990;116(1):100-3.
-
1989: Vormoor J; Ritter J; Creutzig U; Schellong G
[Incidence and prognostic significance of Auer rods in children with acute myeloid leukemia in the studies AML-BFM-78 and -83]
Klinische Pädiatrie 1989;201(4):227-32.
-
1989: Creutzig U; Ritter J; Niederbiermann-Koczy G; Harbott J; Schellong G
[Prognostic significance of eosinophilia in children with acute myeloid leukemia in the studies AML-BFM-78 and -83]
Klinische Pädiatrie 1989;201(4):220-6.
-
1988: Creutzig U; Hofmann J; Ritter J; Schellong G
[Therapy realization and complications in the BFM-83 therapy study of acute myelogenous leukemia]
Klinische Pädiatrie 1988;200(3):190-9.
-
1987: Creutzig U; Ritter J; Budde M; Sutor A; Schellong G
Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia.
Cancer 1987;60(12):3071-9.
-
1987: Creutzig U; Stahnke K; Pollmann H; Sutor A; Ritter J; Budde M; Schellong G
The problem of early death in childhood AML.
Haematology and blood transfusion 1987;30():524-9.
-
1987: Harbott J; Budde M; Creutzig U; Engel R; Fengler R; Rudolph B; Lampert F
Prognostic meaning of chromosome aberrations in acute lymphocytic leukemia and acute nonlymphocytic leukemia patients of the BFM Study Group.
Haematology and blood transfusion 1987;30():497-503.
-
1987: Ludwig W D; Herrmann F; Gatzke A; Budde M; Creutzig U; Ritter J; Schellong G
Surface marker analysis by monoclonal antibodies: a valuable technique in childhood acute myeloid leukemia.
Haematology and blood transfusion 1987;30():418-22.
-
1987: Creutzig U; Cantù-Rajnoldi A; Ritter J; Romitti L; Odenwald E; Conter V; Riehm H; Masera G
Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
The American journal of pediatric hematology/oncology 1987;9(4):324-30.
-
1987: Creutzig U; Ritter J; Budde M; Jürgens H; Riehm H; Schellong G
Treatment results in childhood AML, with special reference to the German studies BFM-78 and BFM-83.
Haematology and blood transfusion 1987;31():30-4.
-
1987: Creutzig U; Ritter J; Riehm H; Budde M; Schellong G
The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis.
Haematology and blood transfusion 1987;30():71-5.
-
1986: Creutzig U; Ritter J; Budde M; Riehm H; Henze G; Lampert F; Gerein V; Müller-Weihrich S; Niethammer D; Spaar H J
[Current results of cooperative AML therapy studies in children: BFM-78 and 83]
Klinische Pädiatrie 1986;198(3):183-90.
-
1986: Fengler R; Baumgarten E; Buchmann S; Creutzig U; Harbott J; Ludwig R; Henze G
[Biclonal leukemia O-ALL/AMoL) with 11;19 translocation and trisomy X in an 8-month-old girl]
Klinische Pädiatrie 1986;198(3):178-82.
-
1985: Hiddemann W; Ritter J; Wörmann B; Budde M; Creutzig U; Schellong G; Büchner T; Riehm H
[DNA aneuploidy in children with acute leukemia: I. Incidence and clinical significance within the scope of the BFM studies]
Klinische Pädiatrie 1985;197(3):215-20.
-
1985: Creutzig U; Brandeis W; Gerein V; Ritter J; Stollmann B; Kabisch H; Niethammer D; Schellong G
[Adult form of chronic myelogenous leukemia in childhood--a retrospective analysis of 20 patients]
Klinische Pädiatrie 1985;197(3):203-6.
-
1985: Creutzig U; Ritter J; Riehm H; Langermann H J; Henze G; Kabisch H; Niethammer D; Jürgens H; Stollmann B; Lasson U
Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78.
Blood 1985;65(2):298-304.
-
1985: Ritter J; Creutzig U; Riehm H J; Brandeis W; Gerein V; Prindull G; Rister M; Schellong G
Improved treatment results in childhood acute myelogenous leukemia: an update of the German cooperative study AML-BFM-78.
Haematology and blood transfusion 1985;29():82-3.
-
1984: Creutzig U; Schaaff A; Ritter J; Jobke A; Kaufmann U; Schellong G
[Acute myelogenous leukemia in children under 2 years of age: studies and treatment results in 23 children in the AML therapy study BFM-78]
Klinische Pädiatrie 1984;196(3):130-4.
-
1983: Creutzig U; Ritter J; Langermann H J; Riehm H; Henze G; Niethammer D; Jürgens H; Stollmann B; Lasson U; Kabisch H; Wahlen W; Löffler H; Schellong G
[Acute myelogenous leukemia in children: results of the cooperative BFM-78 therapy study after 3 3/4 years]
Klinische Pädiatrie 1983;195(3):152-60.
-
1983: Creutzig U; Schellong G; Ritter J; Sutor A H; Riehm H; Langermann H J; Jobke A; Kabisch H
Improved results in treatment of acute myelogenous leukemia in children--report of the German cooperative AML study BFM-78.
Haematology and blood transfusion 1983;28():46-50.
Sign-in to see more
